中國投資開發(00204.HK)獲解除禁制令
中國投資開發(00204.HK)公布,有關兩名原告楊為旭及謝宛霖提出原訴傳票,及高等法院原訟法庭頒令禁止轉讓6.5億股,於上周四(16日),法庭基於相關與訟方的同意及在公司作出承諾不會採取任何措施執行第一原告及第二原告所提供及載錄於禁制令內的損失賠償承諾的情況下、已解除針對公司的禁制令且不就訟費作出命令。
同時,法庭亦在相關與訟方的同意下給予第一原告及第二原告批准在不作訟費命令的情況下,終止對公司(第三被告)及第四至第十二被告的原訴傳票。針對公司(第三被告)及第四至第十二被告的原訴傳票中止通知已於上周五(17日)送達。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.